These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27128533)

  • 1. Missed bleeding events after ticagrelor in PEGASUS trial: Massive non-compliance, information censoring, or both?
    Serebruany V; Tomek A
    Int J Cardiol; 2016 Jul; 215():214-6. PubMed ID: 27128533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
    Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
    Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
    Serebruany VL
    Int J Cardiol; 2015 Dec; 201():508-12. PubMed ID: 26318512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.
    Magnani G; Storey RF; Steg G; Bhatt DL; Cohen M; Kuder J; Im K; Aylward P; Ardissino D; Isaza D; Parkhomenko A; Goudev AR; Dellborg M; Kontny F; Corbalan R; Medina F; Jensen EC; Held P; Braunwald E; Sabatine MS; Bonaca MP
    Eur Heart J; 2016 Jan; 37(4):400-8. PubMed ID: 26443023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
    Bonaca MP; Bhatt DL; Oude Ophuis T; Steg PG; Storey R; Cohen M; Kuder J; Im K; Magnani G; Budaj A; Theroux P; Hamm C; Špinar J; Kiss RG; Dalby AJ; Medina FA; Kontny F; Aylward PE; Jensen EC; Held P; Braunwald E; Sabatine MS
    JAMA Cardiol; 2016 Jul; 1(4):425-32. PubMed ID: 27438319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
    Bonaca MP; Bhatt DL; Braunwald E; Cohen M; Steg PG; Storey RF; Held P; Jensen EC; Sabatine MS
    Am Heart J; 2014 Apr; 167(4):437-444.e5. PubMed ID: 24655690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
    Bonaca MP; Bhatt DL; Steg PG; Storey RF; Cohen M; Im K; Oude Ophuis T; Budaj A; Goto S; López-Sendón J; Diaz R; Dalby A; Van de Werf F; Ardissino D; Montalescot G; Aylward P; Magnani G; Jensen EC; Held P; Braunwald E; Sabatine MS
    Eur Heart J; 2016 Apr; 37(14):1133-42. PubMed ID: 26491109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
    Bhatt DL; Bonaca MP; Bansilal S; Angiolillo DJ; Cohen M; Storey RF; Im K; Murphy SA; Held P; Braunwald E; Sabatine MS; Steg PG
    J Am Coll Cardiol; 2016 Jun; 67(23):2732-2740. PubMed ID: 27046160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.
    Al-Salama ZT; Keating GM; Keam SJ
    Drugs; 2017 Dec; 77(18):2025-2036. PubMed ID: 29150806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.
    Ariotti S; Gargiulo G; Valgimigli M
    Curr Cardiol Rep; 2017 Jan; 19(1):2. PubMed ID: 28097533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.
    Bonaca MP; Storey RF; Theroux P; Steg PG; Bhatt DL; Cohen MC; Im K; Murphy SA; Magnani G; Ophuis TO; Rudah M; Parkhomenko A; Isaza D; Kamensky G; Goudev A; Montalescot G; Jensen EC; Johanson P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2017 Sep; 70(11):1368-1375. PubMed ID: 28882235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.
    Marrugat J; Elosua R; Grau M; Sayols-Baixeras S; Dégano IR
    Rev Esp Cardiol (Engl Ed); 2016 May; 69(5):480-7. PubMed ID: 27062680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PEGASUS - Ticagrelor in secondary prevention on patients after a myocardial infarction].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2015 Jun; 61(6):511-5. PubMed ID: 26258965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
    Serebruany VL
    Cardiology; 2011; 120(3):169-71. PubMed ID: 22418766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term use of ticagrelor in patients with prior heart attack: ticagrelor plus aspirin versus aspirin monotherapy.
    Amico F; Schlesinger A; Mazzoni J
    Postgrad Med; 2016; 128(2):164-9. PubMed ID: 26689345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor FDA approval issues revisited.
    Serebruany VL
    Cardiology; 2012; 122(3):144-7. PubMed ID: 22832506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health.
    Park KH; Jeong MH; Ahn Y; Ahn TH; Seung KB; Oh DJ; Choi DJ; Kim HS; Gwon HC; Seong IW; Hwang KK; Chae SC; Kim KB; Kim YJ; Cha KS; Oh SK; Chae JK;
    Int J Cardiol; 2016 Jul; 215():193-200. PubMed ID: 27128530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction.
    Röshammar D; Nyberg J; Andersson T; Stanski D; Storey RF; Hamrén B
    J Clin Pharmacol; 2017 May; 57(5):573-583. PubMed ID: 27859337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.
    Blin P; Dureau-Pournin C; Lassalle R; Jové J; Thomas-Delecourt F; Droz-Perroteau C; Danchin N; Moore N
    Br J Clin Pharmacol; 2017 Sep; 83(9):2056-2065. PubMed ID: 28345154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
    Barillà F; Pelliccia F; Borzi M; Camici P; Cas LD; Di Biase M; Indolfi C; Mercuro G; Montemurro V; Padeletti L; Filardi PP; Vizza CD; Romeo F;
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18(1):1-9. PubMed ID: 27635937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.